FOXO1 and FYN Expression Trends in Breast Cancer Stem Cells: An Integrative Study of Single Nucleotide Polymorphism (SNP) Array and Quantitative PCR (qPCR) Analysis
Abstract
BACKGROUND: Currently, identification of breast cancer stem cells (BCSCs) commonly relies on CD24-/CD44+ expression profiles. However, few studies have integrated genomic mutation data with experimental gene expression validation in CSC and non-CSC populations. Genotyping results of CD24-/CD44+ MDAMB-231 cells revealed 36 mutations in BCSCs compared to non-BCSCs, with upregulated FOXO1 and FYN that might represent promising candidate biomarkers for this subpopulation. Therefore, in this study, single nucleotide polymorphism (SNP) and quantitative polymerase chain reaction (qPCR) analysis were performed to assess the association between mutations and expression trends of FOXO1 and FYN in MDAMB-231 cell, as breast cancer cell model with stem-like traits and well-characterized profile.
METHODS: Genomic DNA was isolated from BCSC and non-BCSC DNA from the MDAMB-231 cell line. Mutation analysis was conducted using PLINK, while gene expressions of FOXO1 and FYN were quantified by one-step SYBR Green-based qPCR, using 18s rRNA as a reference. Data was then analyzed with the Livak (2−∆∆Ct) method.
RESULTS: Among 36 mutations found in BCSCs of the MDAMB-231 cell line, PTEN (rs786204914) and CHEK2 (rs587782401) were identified as pathogenic. While FOXO1 (2.989±2.817 vs. 1.072±0.388) and FYN (1.405±0.072 vs. 0.855±0.140) mRNA levels were found to be higher in CSCs compared to non-CSCs, though these differences was not statistically significant.
CONCLUSION: Pathogenic mutations in CHEK2 and PTEN were detected within BCSC population, implying a potential influence on the expression of FOXO1 and FYN, though not statistically significant. These findings suggest a possible, but as yet unverified, association between gene mutations and expression patterns, emphasizing the importance of further functional studies to validate FOXO1 and FYN as biomarkers for BCSCs.
KEYWORDS: breast cancer stem cells, FOXO1, FYN, PTEN, CHEK2, mutation, biomarker
Full Text:
PDFReferences
Prayogo AA, Wijaya AY, Hendrata WM, Looi SS, I'tishom R, Hakim L, et al. Dedifferentiation of MCF-7 breast cancer continuous cell line, development of breast cancer stem cells (BCSCs) enriched culture and biomarker analysis. Indones Biomed J. 2020; 12(2): 115-23, CrossRef.
Abdihalim TS, Idris AAA. Mucin level as a potential biomarker for breast cancer diagnosis. Mol Cell Biomed Sci. 2022; 6(3): 117-20, CrossRef.
Meiliana A, Dewi NM, Wijaya A. Cancer stem cell hypothesis: Implication for cancer prevention and treatment. Indones Biomed J. 2016; 8(1): 21-36, CrossRef.
Savitri M, Bintoro UY, Sedana MP, Diansyah MN, Romadhon PZ, Amrita PNA, et al. Circulating plasma miRNA-21 as a superior biomarker compared to CA 15-3: Assessment in healthy age matched subjects and different stageof breast cancer patients. Indones Biomed J. 2020; 12(2): 157-64, CrossRef.
Jangholi E, Tehran HA, Ghasemi A, Hoseinian M, Firoozi S, Ghodsi SM, et al. Evaluation of secretome biomarkers in glioblastoma cancer stem cells: A bioinformatic analysis. Cancer Reports. 2024; 7(7): e2080, CrossRef.
López de Andrés J, Griñán-Lisón C, Jiménez G, Marchal JA. Cancer stem cell secretome in the tumor microenvironment: A key point for an effective personalized cancer treatment. J Hematol Oncol. 2020; 13(1): 136, CrossRef.
Warmoes M, Lam SW, van der Groep P, Jaspers JE, Smolders YHCM, de Boer L, et al. Secretome proteomics reveals candidate non-invasive biomarkers of BRCA1 deficiency in breast cancer. Oncotarget. 2016; 7(39): 63537-48, CrossRef.
Panigoro SS, Siswiandari KM, Paramita RI, Fadilah F, Erlina L. Targeted genome sequencing data of young women breast cancer patients in Cipto Mangunkusumo National Hospital, Jakarta. Data Brief. 2020; 32: 106138, CrossRef.
Liu J, Li S, Li X, Li W, Yang Y, Guo S, et al. Genome wide association study followed by trans-ancestry meta analysis identify 17 new risk loci for schizophrenia. BMC Med. 2021; 19(1): 177, CrossRef.
Suratannon N, van Wijck RTA, Broer L, Xue L, van Meurs JBJ, Barendregt BH, et al. Rapid low cost microarray-based genotyping for genetic screening in primary immunodeficiency. Front Immunol. 2020; 11: 614, CrossRef.
Ay Ly M, Septelia IW, Fadilah F, Rafika IP. Identification of potential breast cancer stem cell biomarkers in the secretome using a network interaction approach analysis. Asian Pacific J Cancer Prev. 2024; 25(5): 1803-13, CrossRef.
Xie Z, Bailey A, Kuleshov MV, Clarke DJB, Evangelista JE, Jenkins SL, et al. Gene set knowledge discovery with enrichr. Curr Protoc. 2021; 1(3): e90, CrossRef.
STRING [Internet]. String Database [cited 2025 Jan 2]. Available from: string-db.org.
Cytoscape [Internet]. Cytoscape [cited 2025 Jan 2]. Available from: cytoscape.org/download.html.
cBioportal for Cancer [Internet] MutationMapper: CHEK2 [cited 2025 Jan 2]. Available from: www.cbioportal.org.
Furusawa Y, Yamanouchi Y, Iizumi T, Zhao QL. Checkpoint kinase 2 is dispensable for regulation of the p53 response but is required for G2/M arrest and cell survival in cells with p53 defects under heat stress. Apoptosis. 2017; 22(10): 1225-34, CrossRef.
Habyarimana T, Attaleb M, Mugenzi P, Mazarati JB, Bakri Y, Mzibri M El. CHEK2 germ line mutations are lacking among familial and sporadic breast cancer patients in Rwanda. 2018; 19(2): 375-9, CrossRef.
Ansari N, Shahrabi S, Khosravi A, Shirzad R, Rezaeean H. Prognostic significance of CHEK2 mutation in cancer. 2019; 50(3): e36-e41, CrossRef.
Ji L hua, Zhang B, Zhao G. Investigation of the potential role of checkpoint kinase 2 in the regulation of gastric cancer stem cells. 2018; 17(4): 605-9, CrossRef.
Marvalim C, Datta A, Lee SC. Role of p53 in breast cancer progression: An insight into p53 targeted therapy. Theranostics. 2023; 13(4): 1421-42, CrossRef.
Sadaf, Hazazi A, Alkhalil SS, Alsaiari AA, Gharib AF, Alhuthali HM, et al. Role of fork-head box genes in breast cancer: from drug resistance to therapeutic targets. Biomedicines. 2023; 11(8): 2159, CrossRef.
Nathansen J, Meyer F, Müller L, Schmitz M, Borgmann K, Dubrovska A. Beyond the double-strand breaks : The role of DNA repair proteins in cancer stem-cell regulation. Cancers. 2021; 13(19): 4818, CrossRef.
Razak NA, Abu N, Ho WY, Zamberi NR, Tan SW. Cytotoxicity of eupatorin in MCF-7 and MDA-MB-231 human breast cancer cells via cell cycle arrest, anti-angiogenesis and induction of apoptosis. Sci Rep. 2019; 9(1): 1514, CrossRef.
Luongo F, Colonna F, Calap F, Vitale S, Fiori ME, Maria R De. PTEN tumor-suppressor: The dam of stemness in cancer. Cancers. 2019; 11(8): 1076, CrossRef.
cBioportal for Cancer [Internet] MutationMapper: PTEN [cited 2025 Jan 2]. Available from: www.cbioportal.org.
Yndestad S. The role of PTEN, PI3K-Akt- mTOR signaling and pseudogene PTENP1 in breast cancer [Thesis]. Bergen: University of Bergen; 2018, bora.uib.no.
González-sánchez A, Jaraíz-rodríguez M, Domínguez-prieto M. Connexin43 recruits PTEN and Csk to inhibit c-Src activity in glioma cells and astrocytes. Oncotarget. 2016; 7(31): 49819-33, CrossRef.
Tserga A, Chatziandreou I, Michalopoulos N V. Mutation of genes of the PI3K / AKT pathway in breast cancer supports their potential importance as biomarker for breast cancer aggressiveness. Virchows Arch. 2016; 469(1): 35-43, CrossRef.
Deng Y, Wang F, Hughes T, Yu J, State TO, Hospital JC. FOXOs in cancer immunity: Knowns and unknowns. Semin Cancer Biol. 2018; 50: 53-64, CrossRef.
Yu J mei, Sun W, Wang Z he, Liang X, Hua F, Li K, et al. TRIB3 supports breast cancer stemness by suppressing FOXO1 degradation and enhancing SOX2 transcription. Nature Communications. 2019; 10: 5720, CrossRef.
Shen H, Wang D, Li L, Yang S, Chen X, Zhou S, et al. MiR-222 promotes drug-resistance of breast cancer cells to adriamycin via modulation of PTEN/Akt/FOXO1 pathway. Gene. 2017; 596: 110-8, CrossRef.
Khan MA, Massey S, Ahmad I, Akhter N. FOXO1 gene downregulation and promoter methylation exhibits significant correlation with clinical parameters in Indian breast cancer patients. Front Genet. 2022; 13: 842943, CrossRef.
Dilmac S, Kuscu N, Caner A, Yildirim S, Yoldas B, Farooqi AA, et al. SIRT1 / FOXO signaling pathway in breast cancer progression and metastasis. Int J Mol Sci. 2022; 23(18): 10227, CrossRef.
Hornsveld M, Feringa FM, Krenning L, Dansen TB, Medema H, Burgering BMT. A FOXO-dependent replication checkpoint restricts proliferation of damaged cells. Cell Rep. 2021; 34(4): 108675, CrossRef.
Xing YQ, Li A, Yang Y, Li XX, Zhang LN, Guo HC. The regulation of FOXO1 and its role in disease progression. Life Sci. 2018; 193: 124-31, CrossRef.
Chandrashekar DS, Afaq F, Kumar S, Athar M, Shrestha S, Singh R, et al. Neoplasia Bromodomain inhibitor treatment leads to overexpression of multiple kinases in cancer cells. Neoplasia. 2024; 57: 101046, CrossRef.
Peng SF, Fu Y. FYN: Emerging biological roles and potential therapeutic targets in cancer. J Transl Med. 2023; 21(1): 84, CrossRef.
Elias D, Ditzel HJ. FYN is an important molecule in cancer pathogenesis and drug resistance. Pharmacol Res. 2015; 100: 250-4, CrossRef.
Xie YG, Yu Y, Hou LK, Wang X, Zhang B, Cao XC. FYN promotes breast cancer progression through epithelial-mesenchymal transition. Oncol Rep. 2016; 36(2): 1000-6, CrossRef.
Salamah R, Wijayanti N, Widiyanto S. n-hexane fraction of Cucumis melo L. cultivar gama melon parfum: An in vitro study in MCF7 and T47D cells line. Mol Cell Biomed Sci. 2025; 9(2): 76-81, CrossRef.
DOI: https://doi.org/10.18585/inabj.v17i4.3656
Copyright (c) 2025 The Prodia Education and Research Institute
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Indexed by:
The Prodia Education and Research Institute
